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Abstract
Background: Local anesthetics alleviate neuropathic pain in some cases in clinical practice, and exhibit longer
durations of action than those predicted on the basis of the pharmacokinetics of their blocking effects on voltage-
dependent sodium channels. Therefore, local anesthetics may contribute to additional mechanisms for reversal of
the sensitization of nociceptive pathways that occurs in the neuropathic pain state. In recent years, spinal glial cells,
microglia and astrocytes, have been shown to play critical roles in neuropathic pain, but their participation in the
analgesic effects of local anesthetics remains largely unknown.
Results: Repetitive epidural administration of ropivacaine reduced the hyperalgesia induced by chronic constrictive
injury of the sciatic nerve. Concomitantly with this analgesia, ropivacaine suppressed the increases in the
immunoreactivities of CD11b and glial fibrillary acidic protein in the dorsal spinal cord, as markers of activated
microglia and astrocytes, respectively. In addition, epidural administration of a TrkA-IgG fusion protein that blocks
the action of nerve growth factor (NGF), which was upregulated by ropivacaine in the dorsal root ganglion,
prevented the inhibitory effect of ropivacaine on microglia, but not astrocytes. The blockade of NGF action also
abolished the analgesic effect of ropivacaine on neuropathic pain.
Conclusions: Ropivacaine provides prolonged analgesia possibly by suppressing microglial activation in an NGF-
dependent manner and astrocyte activation in an NGF-independent manner in the dorsal spinal cord. Local
anesthetics, including ropivacaine, may represent a new approach for glial cell inhibition and, therefore, therapeutic
strategies for neuropathic pain.
Background
Neuropathic pain is an extremely severe chronic pain
caused by damage to the nervous system itself. In clini-
cal practice, this pain syndrome remains a major issue
because of the limited and variable effectiveness of exist-
ing analgesics [1]. Such poor effectiveness can be partly
attributed to insufficient understanding of the analgesic
mechanisms of existing drugss u c ha so p i o i d s ,a n t i c o n -
vulsants and antidepressants. Systemic and epidural
applications of local anesthetics relieve neuropathic pain
in some cases, but the underlying mechanisms remain
unclear because the effects occur at lower doses than
the effective doses for blocking voltage-gated sodium
channels, the primary targets of local anesthetics [2].
Furthermore, the analgesic effects of drugs persist for
longer durations than those predicted on the basis of
their pharmacokinetics [3-5]. It has been reported that
local anesthetics affect other ion channels and G
protein-coupled receptors [2], and these effects are sug-
gested to partially contribute to the analgesia observed
with local anesthetics [2,6]. Local anesthetics also inhibit
the phosphorylation of p38 mitogen-activated protein
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ropathic pain [7,8]. However, the glial participation in
the analgesic effects of local anesthetics remains
speculative.
Microglia and astrocytes are the dominant glial cells in
the central nervous system and play critical roles in neu-
roinflammation and neuronal plasticity via active
communication with neurons [9,10]. In response to per-
ipheral nerve injury, these glial cells become activated
and release a variety of proinflammatory mediators such
as cytokines and chemokines in the dorsal spinal cord
[11-14]. These proinflammatory mediators act on noci-
ceptive neurons, resulting in augmentation of nociceptive
signal transmission or central sensitization. In line with
these findings, it has been reported that intrathecal
administration of compounds that suppress the activation
of glial cells or antagonists of proinflammatory mediators
alleviates neuropathic pain [11-13,15-18]. Therefore,
modulating glial cell function appears to represent a pro-
mising therapeutic strategy for neuropathic pain.
Nerve growth factor (NGF) is a founding member of
the neurotrophic factor family and is well known to be
involved in nociceptor function [19]. In the periphery,
NGF is released in response to inflammation and subse-
quently acts on its high-affinity receptor, TrkA,
expressed on a subset of nociceptive dorsal root gang-
lion (DRG) neurons, resulting in hyperalgesia [19]. On
the other hand, NGF has a beneficial impact on neuro-
pathic pain when administered intrathecally [20,21].
NGF promotes functional regeneration of damaged
DRG neurons [22] and improves neuropathy in strepto-
zotocin-induced diabetic rats [23]. NGF ameliorates the
increased expressions of c-jun and ATF3 in DRG neu-
rons caused by nerve injury, suggesting its involvement
in the protection of neurons [24,25]. It has also been
reported that NGF suppresses activated astrocytes in
association with pain relief [26]. Thus, the roles of NGF
in neuropathy are considerably complicated.
Ropivacaine was developed as an alternative to bupiva-
caine, which has more severe toxicity, and at present it
is widely used as an epidural anesthetic at concentra-
tions of 0.2-1% in clinical practice [27]. Ropivacaine
shows increased cardiovascular safety and a shorter
elimination half-life compared with bupivacaine [27-29].
Recently, we reported that the content of NGF was
upregulated in the injured DRG after repetitive epidural
administration of 0.2% ropivacaine [30]. This finding
implies that NGF produced endogenously upon ropiva-
caine treatment plays a role in the process of pain
reduction. Therefore, in the present study, we further
investigated the involvement of NGF in the analgesic
effect of ropivacaine in a rat model of neuropathic pain
with a focus on the spinal glial cells.
Results
Prolonged analgesic effect of repetitive epidural
administration of ropivacaine on neuropathic pain
Before the chronic constrictive injury (CCI) operation
on day 0, the latencies of ipsilateral paw withdrawal
from thermal stimulation in rats assigned to a ropiva-
caine treatment group and a saline treatment group
were 13.4 ± 0.5 s and 13.2 ± 0.9 s, respectively (n =8 - 9 ;
Figure 1a). After the CCI operation, the latencies began
to decrease significantly on the ipsilateral side from day
3( 7 . 8±0 . 3sf o rr o p i v a c a i n et r e a t m e n ta n d7 . 6±0 . 5s
for saline treatment; p <0 . 0 0 1f o rb o t ht r e a t m e n t s ;
Figure 1a). The latencies on the contralateral side were
unchanged (Figure 1a).
Next, we examined the effect of repetitive epidural
administration of 0.2% ropivacaine on the thermal
hyperalgesia in CCI rats. Epidural administration of
ropivacaine or saline was commenced at day 7 after the
CCI operation, when the hyperalgesia had become
established, and was continued once daily for 7 days.
Motor paralysis was observed for about 10 min immedi-
ately after the epidural injection of ropivacaine, but the
paralysis was limited to the hindlimbs in all of the rats
examined, as described by Durant and Yaksh [31]. Such
behavioral changes confirmed that ropivacaine had been
successfully delivered to the epidural space around the
lumbar third (L3) vertebral level and suggested that
ropivacaine at least transiently inhibited the voltage-
gated sodium channels in this protocol. The thermal
hyperalgesia of CCI rats was significantly relieved at 3
days after the beginning of ropivacaine treatment com-
pared with CCI rats administered saline (12.8 ± 0.8 s for
ropivacaine treatment and 7.4 ± 0.9 s for saline
treatment; p < 0.001; n =8 - 9 ;F i g u r e1 a ) .T h et h e r m a l
hyperalgesia had almost returned to the basal level at
day 13 (13.5 ± 0.5 s before CCI and 12.3 ± 0.9 s after
CCI plus ropivacaine). Treatment with ropivacaine and
saline did not affect the contralateral paw withdrawal
latencies in response to the thermal stimulus (14.4 ±
1.0 s for ropivacaine treatment and 14.1 ± 1.1 s for sal-
ine treatment at day 13; n = 8-9; Figure 1a). The analge-
sic effects of other concentrations of ropivacaine were
also examined. Ropivacaine reduced the thermal hyper-
algesia in a dose-dependent manner in the concentra-
tion range of 0.1-0.75% at day 10 (n = 4-9; Figure 1b).
Furthermore, we investigated the duration of analgesia
induced by repetitive epidural ropivacaine administra-
tion. Ropivacaine administration to CCI rats was
commenced from day 7, but discontinued after the
administration at day 10, at which time point the recov-
ery from the hyperalgesia was established by the
repeated ropivacaine injections. After the cessation of
ropivacaine administration, the significant reduction of
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Figure 1 Effect of epidural ropivacaine treatment on thermal hyperalgesia in CCI rats. (a) The latencies for paw withdrawal on the
ipsilateral (left panel) and contralateral (right panel) sides in response to thermal stimuli applied to the corresponding hindpaw pad in rats with
CCI were evaluated. Ropivacaine (open circles) or saline (closed circles) was epidurally administered once daily from days 7 to 13, as indicated by
the horizontal bars. **p < 0.01 and ***p < 0.001 compared with the values in CCI rats treated with saline on the corresponding days by an
unpaired t-test (n = 8-9).
###p < 0.001 compared with the values on the preoperative day by Dunnett’s multiple comparison test (n = 8-9).
(b) The dose-dependent effects of epidural ropivacaine on the thermal hyperalgesia were examined at day 10.
##p < 0.01 and
###p < 0.001
compared with the values in CCI rats treated with saline by Dunnett’s multiple comparison test (n = 4-9). (c) The duration of analgesia induced
by ropivacaine was examined. Ropivacaine was epidurally administered once daily from days 7 to 10, as indicated by the horizontal bars.
#p < 0.05 compared with the values before ropivacaine administration at day 7 by Dunnett’s multiple comparison test (n = 4).
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Page 3 of 11the thermal hyperalgesia persisted for at least 2 days (7.5
± 0.8 s at day 7 before ropivacaine administration and
11.6 ± 0.9 s at day 12; p <0 . 0 5 ;n =4 ;F i g u r e1 c ) ,a n d
then the analgesic effect gradually declined (Figure 1c).
Suppression of activated spinal glial cells by ropivacaine
administration
To examine the involvement of spinal glial cells in the
ropivacaine-induced analgesia, we analyzed the expres-
sions of glial cell activation markers in the spinal dorsal
horn of CCI rats. The immunoreactivity for CD11b, a
microglial activation marker, was significantly increased
in the ipsilateral spinal dorsal horn at day 14 after CCI
(64.2 ± 1.7 a.u.) compared with control intact rats (29.8
±1 . 6a . u . ;p <0 . 0 0 1 ;n =4 ;F i g u r e2 aa n d2 b ) .T h e
immunoreactivity for glial fibrillary acidic protein
(GFAP, an astrocyte activation marker) was also signifi-
cantly increased on the ipsilateral side (56.3 ± 4 a.u. for
CCI rats and 28.6 ± 1.5 a.u. for control intact rats; p <
0.001; n =4 ;F i g u r e2 aa n d2 b ) .T h eC D 1 1 b - e x p r e s s i n g
and GFAP-expressing cells changed their morphologies
to amoeboid and hypertrophied with thick processes,
respectively, indicating their activation after the CCI
operation (Figure 2a). In ropivacaine-treated CCI rats,
the immunoreactivity for CD11b was significantly
decreased compared with saline-treated CCI rats (37.8 ±
1.9 a.u. for ropivacaine treatment and 64.2 ± 1.7 a.u. for
saline treatment; p < 0.001; n =4 ;F i g u r e2 aa n d2 b ) .
The immunoreactivity for GFAP was also decreased
after ropivacaine treatment (33.0 ± 3.3 a.u.; p < 0.01; n
=4 ;F i g u r e2 aa n d2 b ) .T h em o r p h o l o g i c a lc h a n g e so f
the microglia and astrocytes were suppressed by ropiva-
caine treatment (Figure 2a). On the contralateral side,
the immunoreactivities for both CD11b and GFAP were
slightly, but significantly, increased (Figure 2), as
described in previous reports [32,33]. These increases in
immunoreactivity were also decreased after ropivacaine
treatment (Figure 2).
Effects of blockade of NGF action on the ropivacaine-
induced suppression of activated spinal glial cells
As previously described [30], the NGF content in the
lumbar fourth (L4) DRG on the ipsilateral, but not con-
tralateral, side of CCI rats was significantly increased by
ropivacaine treatment (p < 0.01 compared with control
intact rats and p < 0.05 compared with CCI rats with
saline treatment; n = 8-9; Figure 3a). To clarify the
involvement of NGF in the inhibitory effect of ropiva-
caine on the activated glial cells, we blocked the action
of NGF in CCI rats with ropivacaine treatment and
examined its effect on glial activation at day 10. NGF
was specifically blocked with a recombinant rat TrkA-Fc
chimera by sequestration of endogenous NGF. In
CCI rats with ropivacaine, the suppression of the
morphological change in microglia after CCI was
blocked by prior administration of the TrkA-Fc chimera
(Figure 3b). In contrast, the suppression of the morpho-
logical change of astrocytes was not affected by the
blockade of NGF action (Figure 3b). Densitometric ana-
lysis revealed that the inhibitory effect of ropivacaine on
the immunoreactivity for CD11b on the ipsilateral side
was significantly blocked by treatment with the TrkA-Fc
chimera compared with treatment with the control
IgG1-Fc protein or saline at day 10 (65.5 ± 3.8 a.u. for
TrkA-Fc treatment, 41.7 ± 5.3 a.u. for IgG1-Fc treatment
and 40.4 ± 1.2 a.u. for saline treatment; p <0 . 0 1 ;n =4 ;
Figure 3c). In addition, the inhibitory effect of ropiva-
caine on the immunoreactivity for GFAP on the ipsilat-
eral side was not significantly blocked by treatment with
the TrkA-Fc chimera at day 10 (44.8 ± 2.4 a.u. for
TrkA-Fc treatment, 42.8 ± 2.8 a.u. for IgG1-Fc treatment
and 38.6 ± 2.0 a.u. for saline treatment; n = 4; Figure 3c).
On the contralateral side, the immunoreactivities for
both CD11b and GFAP were unchanged among the CCI
rats with each treatment (Figure 3b and 3c).
Effect of blockade of NGF action on the ropivacaine-
induced analgesia
We further examined the effect of the TrkA-IgG chi-
mera on the ropivacaine-induced analgesia in CCI rats.
Prior administration of the TrkA-IgG chimera signifi-
cantly inhibited the ropivacaine-induced alleviation of
the thermal hyperalgesia in CCI rats on day 10 com-
pared with administration of the control IgG1-Fc pro-
tein (7.0 ± 0.3 s for TrkA-Fc treatment and 11.5 ± 0.9
sf o rI g G 1-Fc treatment; p <0 . 0 1 ;n =5 ;F i g u r e4 ) .T h e
treatments with the control IgG1-Fc protein and TrkA-
Fc chimera did not affect the contralateral paw with-
drawal (13.4 ± 1.1 s for TrkA-Fc treatment and 13.6 ±
0.7 s for IgG1-Fc treatment; n =5 ;F i g u r e4 ) .H o w e v e r ,
chronic intrathecal administration of NGF (3 μg/day)
from days 7 to 14 in CCI rats did not relieve the ther-
mal hyperalgesia on day 14 after CCI (8.0 ± 0.3 s for
NGF treatment and 8.9 ± 0.6 s for vehicle treatment; n
= 3-4). Even a high dose of NGF (12 μg/day) could not
ameliorate the thermal hyperalgesia (7.5 ± 1.0 s at day
14; n =2 ) .
Discussion
In this study, we have shown for the first time that repe-
titive epidural administration of the local anesthetic
ropivacaine suppressed both activated microglia and
astrocytes concurrently with alleviation of thermal
hyperalgesia in a rat model of neuropathic pain.
Furthermore, upregulated NGF in the injured DRG was
involved in the suppression of activated microglia, but
not astrocytes, and may contribute to the prolonged
analgesic effect of ropivacaine.
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Figure 2 Effects of epidural ropivacaine treatment on the activated spinal glial cells in CCI rats. (a) Representative images of
immunohistochemical staining for CD11b (a microglial activation marker) and GFAP (an astrocyte activation marker) in the L4 spinal dorsal horn.
L4 spinal cords were obtained from control intact rats, CCI rats treated with saline and CCI rats treated with ropivacaine at day 14 after CCI. Scale
bar, 200 μm. Insets: High-magnification views of immunoreactive cells. Scale bar, 5 μm. (b) Densitometric quantification of CD11b and GFAP
immunoreactivities on the ipsilateral and contralateral sides. *p < 0.05, **p < 0.01 and ***p < 0.001 by Tukey-Kramer’s multiple comparison test
(n = 4).
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Figure 3 Effects of the TrkA-Fc chimera on the ropivacaine-induced suppression of activated glial cells in CCI rats. (a) The NGF contents
on the contralateral and ipsilateral sides were measured in control intact rats (white columns), CCI rats treated with epidural saline (black
columns) and CCI rats treated with epidural ropivacaine (grey columns). *p < 0.05 and **p < 0.01 by Tukey-Kramer’s multiple comparison test
(n = 8-9). (b) Representative images of immunohistochemical staining for CD11b (a microglial activation marker) and GFAP (an astrocyte
activation marker) in the L4 spinal dorsal horn. L4 spinal cords were obtained from CCI rats treated with the TrkA-Fc chimera and ropivacaine,
CCI rats treated with the control IgG1-Fc protein and ropivacaine, and CCI rats treated with saline and ropivacaine at day 10 after CCI. Scale bar,
200 μm. (c) Densitometric quantification of the CD11b and GFAP immunoreactivities. **p < 0.01 by Tukey-Kramer’s multiple comparison test
(n = 4).
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Page 6 of 11In recent years, microglia have been increasingly
receiving much attention due to their potential as thera-
peutic targets for intractable pain. Many compounds
that modify microglial function successfully alleviate
neuropathic pain [15,16,18]. Consistently, the present
study showed that ropivacaine suppressed activated
microglia and relieved neuropathic pain via the upregu-
lation of NGF expression in the DRG, suggesting NGF-
dependent microglial inhibition by ropivacaine. Thus,
NGF upregulated in the DRG by ropivacaine may act on
microglia through transport along the DRG axons and
be released into the spinal cord. Under some conditions,
NGF receptors, TrkA and p75 neurotrophin receptors,
are reported to be expressed in microglia and to be
involved in their function [34-37]. Alternatively, NGF
may diminish the injury-induced expression of activators
for microglia in DRG neurons. It is well known that
NGF is a key neurotrophic factor for maintaining the
function of a subpopulation of DRG neurons [38] and
restores damaged functions of the primary afferents in a
wide range of disorders [22,23,39-41]. Upon nerve
injury, DRG neurons begin to release CCL2 in the dor-
sal spinal cord, leading to microglial activation
[11,42,43]. On the contrary, interleukin (IL)-10, an anti-
inflammatory cytokine, is also increased after nerve
injury [44]. IL-10 suppresses the p38 MAPK activation
and tumor necrosis factor-a expression in microglia
activated by lipopolysaccharide [45]. Therefore, NGF
may modulate the expression of injury-induced cyto-
kines in the DRG neurons, and thereby indirectly pre-
vent the activation of microglia.
The ropivacaine-induced analgesia was abolished by
NGF blockade, whereas NGF by itself, even at quite a
high dose, could not relieve neuropathic pain. While it is
well established that NGF has a hyperalgesic action in
the periphery [19], the roles of NGF in nociceptive mod-
ulation in the spinal cord are still controversial. It was
reported that intrathecal administration of NGF induces
thermal hyperalgesia in intact rats [46]. On the contrary,
other reports have indicated that NGF may be rather
beneficial for the treatment of neuropathic pain when
administered intrathecally [20,21,26]. Although the rea-
son for the discrepancy in the results is not yet under-
stood, the present study implies that ropivacaine could
be a feasible lead compound for local upregulation of
N G Fi nt h ei n j u r e dD R G .A l t h o u g hw ec a n n o ts p e c u l a t e
at present that all local anesthetics have an NGF-upregu-
lation effect similar to ropivacaine, further studies using
other drugs seem to be warranted because other local
anesthetics, including butamben [47], bupivacaine [3,48]
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Figure 4 Effect of the TrkA-Fc chimera on the analgesic effect of ropivacaine in CCI rats. The latencies for paw withdrawal on the
ipsilateral (left panel) and contralateral (right panel) sides in response to thermal stimuli in CCI rats were evaluated. Ropivacaine and the TrkA-Fc
chimera (open circles) or control IgG1-Fc protein (closed circles) were epidurally administered once daily from days 7 to 9, as indicated by the
horizontal bars. **p < 0.01 compared with the values in CCI rats treated with the IgG1-Fc protein on the corresponding days by an unpaired
t-test (n = 5).
##p < 0.01 and
###p < 0.001 compared with the values on the preoperative day by Dunnett’s multiple comparison test (n = 5).
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Page 7 of 11and lidocaine [4,5,7], have similar long-term analgesic
effects to ropivacaine. In the present study, ropivacaine
dose-dependently reduced the pain-related behavior. At
all concentrations of ropivacaine examined, the rats
showed transient motor paralysis after administration of
ropivacaine. This dose-dependency could be interpreted
as an analgesic effect of ropivacaine that is related to vol-
tage-gated sodium channel blockade. However, the
experiment examining the prolonged effect of ropiva-
caine showed that the analgesic effect of 0.2% ropivacaine
continued for at least 2 days after the recovery from the
hyperalgesia that was established at day 10 by the
repeated daily injections. Therefore, the prolonged effect
of ropivacaine in the present study seems to be beyond
the transient voltage-gated sodium channel blockade. In
addition to voltage-gated sodium channel blockade, local
anesthetics are known to affect many different molecules
including G protein-coupled receptors and immune cells
[2]. Therefore, molecular targets other than voltage-gated
sodium channels may contribute to the NGF upregula-
tion and prolonged analgesic effect, although the channel
blockade may initiate these processes.
Astrocytes have also been shown to play an important
role in neuropathic pain [11,13], although much less is
known about the molecular basis. Upon activation,
astrocytes increase their synthesis of inflammatory fac-
tors similar to microglia [11,12], and compounds that
inhibit activated astrocytes have been shown to attenu-
ate neuropathic pain [12,17]. Consistent with these find-
ings, activated astrocytes were also inhibited by
ropivacaine treatment. However, the ropivacaine-
induced suppression of activated astrocytes was not
prevented by blockade of NGF action. Therefore, the
inhibitory effect of ropivacaine on astrocyte activation
seems to be NGF-independent, in clear contrast to the
effect on microglia. It still remains to be elucidated
whether the inhibition of astrocyte activation is required
for the analgesic effect of ropivacaine.
Conclusions
The present study has shown that ropivacaine sup-
pressed activated microglia and astrocytes in the spinal
dorsal horn in a neuropathic pain state, concomitantly
with the alleviation of pain. The suppression of activated
microglia and the analgesic effect of ropivacaine were
mediated by NGF signaling. These results suggest that
epidural local anesthetics, including ropivacaine, may
represent a new approach for glial cell inhibition and,
therefore, therapeutic strategies for neuropathic pain.
Methods
Experimental animals
All experimental procedures were approved by the Nip-
pon Medical School Animal Care and Use Committee
(Approval number 21-036) and carried out in accor-
dance with the guidelines of the International Associa-
tion for the Study of Pain [49]. Male Sprague-Dawley
rats (weighing 220-300 g at the time of surgery) were
used for all experiments. All surgical procedures were
performed on rats that were deeply anesthetized with
sodium pentobarbital (50 mg/kg, intraperitoneally). The
rats were singly housed under a 14-h light cycle and
received food and water ad libitum.
Production of a neuropathic pain model
To induce neuropathic pain, the rats were subjected to
CCI essentially as described previously [50], except that
4-0 silk thread was used instead of chromic gut. The left
(ipsilateral) sciatic nerve was exposed at the mid-thigh
level and four 4-0 silk threads were loosely ligated
around the nerve at intervals of approximately 1 mm.
The incision was closed with a 4-0 silk suture. The right
(contralateral) sciatic nerve was left intact. Control
intact rats were housed without any surgery until tissue
sampling.
Epidural catheterization
For epidural administration of drugs, a polyethylene
catheter (PE-10; Natsume, Tokyo, Japan) was implanted
into the epidural space at day 6 after CCI, as previously
described [31]. Briefly, a catheter filled with saline was
gently introduced from the base of the lumbar fifth (L5)
spinous process into the lumbar epidural space to a
length of 2 cm, so that its tip was located at the L3-L4
level. The catheter was then flushed with 100 μlo fs a l -
ine to ensure that was no leakage from the epidural
space. The catheter was tied with a loose knot at a level
between the L5 and lumbar sixth (L6) vertebrae and
secured to superficial lumbar muscles. The catheter was
then tunneled subcutaneously to the surface of the neck
skin and fixed to its fascia. Catheter-implanted rats
without obvious movement disturbances, such as paraly-
sis, were used in subsequent experiments. After comple-
tion of the experimental series, we confirmed that the
tip of the catheter was appropriately located in the epi-
dural space at the L3-L4 level. Furthermore, in prelimin-
ary experiments, we confirmed that dye injected through
the catheter was reliably delivered to the epidural, but
not the subdural, space around the L3-L4 level.
Epidural administration of drugs
One hundred microliters of 0.1%, 0.2% or 0.75% ropiva-
caine (AstraZeneca, Osaka, Japan) or saline was slowly
injected for 30 s through the epidural catheter, followed
by 20 μl of saline. Except for the experiment examining
the dose-dependent effects of ropivacaine, 0.2% ropiva-
caine was used in all experiments. As we reported pre-
viously [27], this dose of ropivacaine caused the rats to
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administration, but no other systemic effects during the
experiments. Ropivacaine was administered once daily
from days 7 to 13 after CCI. In the experiment to exam-
ine the duration of ropivacaine analgesia, ropivacaine
was administered once daily from days 7 to 10. To
block the actions of NGF, a recombinant rat TrkA-Fc
chimera (Recombinant Rat TrkA-Fc Chimera; R&D Sys-
tems, Minneapolis, MN) was epidurally injected at 1 h
before ropivacaine administration from days 7 to 9 after
CCI. As a control, a recombinant human IgG1-Fc pro-
tein (R&D Systems) or saline was injected. Both recom-
binant proteins were dissolved in sterile saline (0.1 μg/
μl) and were epidurally administered at a dose of 50 μl,
followed by 20 μl of saline.
Intrathecal catheterization and NGF administration
An intrathecal catheter was inserted on the same day as
the CCI surgery, according to a previously described
method [51]. Briefly, a polyethylene catheter (PE-10) was
inserted into the subarachnoid space through a slit
between the L5 and L6 vertebrae and advanced by 2 cm
to reach the lumbar enlargement of the spinal cord. The
insertion of the catheter into the subarachnoid space was
verified by cautious aspiration of cerebrospinal fluid. Rats
displaying obvious hind limb paralysis were excluded
from the study. At 7 days after CCI and catheterization,
the free extremity of the catheter was connected to an
osmotic pump (model 2001; Alzet, Cupertino, CA) filled
with 125 or 500 ng/μl of rat recombinant b-NGF (Sigma-
Aldrich, St. Louis, MO) dissolved in saline containing 1
μg/μl of rat serum albumin (Sigma-Aldrich). Saline with
albumin was used as a control. The drug was pumped
out at a rate of 1 μl/h for 7 days.
Behavioral test
Thermal hyperalgesia was assessed using a Plantar Test
(Ugo Basile, Varese, Italy) on day 0 before and on days 3,
7, 10 and 13 after CCI. From days 7 to 13, a behavioral
test was performed before drug administration. Briefly,
each rat was placed on a glass plate with a radiant heat
generator (a 55-W halogen reflector bulb) underneath.
After an acclimation period, radiant heat was applied to
either the contralateral or ipsilateral hindpaw pad inde-
pendently. The latency of paw withdrawal from the ther-
mal stimuli was measured twice at 5-min intervals and
t h ea v e r a g ev a l u ew a sa d o p t e d .S i n c eo u rp r e v i o u ss t u d y
revealed that ropivacaine was less effective at treating
mechanical allodynia [30], we focused on thermal hyper-
algesia to examine the behavioral effect of ropivacaine.
Two-site enzyme immunoassay for NGF
The NGF protein concentrations were measured by a
two-site enzyme immunoassay (EIA) [52]. At 14 days
after CCI, the portions of the ipsilateral and contralat-
eral sides of the L4 DRG were immediately dissected,
frozen in liquid nitrogen and stored at -80°C. Each tis-
sue was homogenized using a Polytron homogenizer
( N I T I - O N ,C h i b a ,J a p a n )i n5 0 0μl of homogenization
buffer (50 mM Tris-HCl pH 7.5, 0.5 M NaCl, 0.3% Tri-
ton X-100) containing protease inhibitors (Complete
Mini; Roche Diagnostics, Mannheim, Germany). The
homogenate was centrifuged at 12,000 rpm for 30 min
at 4°C and the supernatant was used for NGF measure-
ment. EIA titer plates (FluoroNunc Module Plates;
Nunc, Roskilde, Denmark) were coated with a primary
polyclonal antibody against NGF (20 ng/well; Promega,
Madison, WI) overnight and then blocked with EIA buf-
fer (50 mM Tris-HCl pH 7.5, 0.5 M NaCl, 0.3% Triton
X-100, 0.4% bovine albumin, 0.4% gelatin) at 4°C for
more than 3 h. Next, 100 μl of each tissue extract or 1-
1000 pg of NGF-b standard (recombinant human NGF-
b; Chemicon, Temecula, CA) in EIA buffer was placed
in each well and the plates were incubated for 7 h at
room temperature. After three washes with EIA buffer
without bovine serum albumin, 100 μlo fa na n t i - N G F
monoclonal antibody conjugated to b-galactosidase (5
μg/ml; Boehringer Mannheim, Mannheim, Germany) in
EIA buffer was added to each well and the plates were
incubated for 12-18 h at room temperature. After a sub-
sequent incubation with 200 μM 4-methylumbelliferyl
b-D-galactoside (Sigma-Aldrich) in 50 mM sodium
phosphate buffer (pH 7.3) containing 10 mM MgCl2 for
24 h in the dark at room temperature, the resulting
fluorescent products were measured using a Spectrafluor
Plus Microplate Reader (Tecan, Salzburg, Austria) with
excitation at 355 nm and emission at 460 nm.
Immunohistochemistry
The rats were perfused transcardially with phosphate-
buffered saline (PBS; pH 7.2) followed by freshly pre-
pared 4% paraformaldehyde in PBS (pH 7.4). The L4
spinal cord was dissected out, post-fixed in the same
fixative at 4°C overnight and then cryoprotected in 20%
sucrose in PBS at 4°C overnight. Subsequently, the
spinal cord was rapidly frozen in dry ice/acetone and
cut into 16-μm transverse sections using a cryostat
(Leica Microsystems, Wetzlar, Germany). The sections
were preincubated in PBS containing 5% normal donkey
serum and 0.2% Triton X-100 at room temperature for
30 min and then incubated with a mouse monoclonal
anti-CD11b antibody (OX-42, a microglial activation
marker; 1:1000 dilution; Serotec, Oxford, UK) or a rab-
bit polyclonal anti-GFAP antibody (1:300 dilution; Dako
Cytomation, Glostrup, Denmark) at 4°C overnight. The
specificity of the anti-GFAP antibody was shown in a
previous study [53]. After washing with PBS,
the sections were incubated with an Alexa Fluor
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tion; Life Technologies, Carlsbad, CA) or an Alexa Fluor
488-conjugated anti-rabbit IgG antibody (1:1000 dilu-
tion; Life Technologies). Images were captured using a
high-resolution digital camera (DP71; Olympus, Tokyo,
Japan) equipped with a computer. To quantify the
immunofluorescence intensity, two sections (minimum
separation, 100 μm) from the L4 spinal cord were exam-
ined per animal. The dorsal horn was densitometrically
analyzed using a computerized image analysis system
(ImageJ; NIH, Bethesda, MA). Data are presented as the
average signal value in arbitrary units (a.u.) from 0 to
255 per pixel. All of the quantitative analyses were per-
formed by a blinded tester.
Statistical analysis
Values are expressed as means ± SEM. Differences in
the paw withdrawal latencies before and after surgery or
ropivacaine administration, and on the ipsilateral and
contralateral sides of the hindpaws on the corresponding
d a yw e r ea n a l y z e db yD u n n e t t ’sm u l t i p l ec o m p a r i s o n
test and an unpaired t-test, respectively. The Tukey-
Kramer multiple comparison test was used to compare
the NGF contents and immunofluorescence intensities
of CD11b and GFAP among control intact rats, CCI
rats and CCI rats with ropivacaine treatment and
among CCI rats treated with the TrkA-Fc chimera, con-
trol IgG1-Fc protein and saline. Values of p < 0.05 were
considered to indicate statistical significance.
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